2Erol UMD,Patti CRN.Effectiveness of loxapine succinate in acutely ill schizophrenic outpatients[J].Curr Ther Res,1979,25(1):144
二级参考文献8
1[1]Kapur S, Zipursky RB, Jones C, et al. The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology.1996 Dec; 15(6): 562～566
2[2]Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994 Mar;268(3) :1403～1410
3[3]Singh AN, Barlas C, Singh S, et al. A neurochemieal basis for the antipsychotie activity of loxapine: interactions with dopamine D1, D2 ,D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry-Neurosci.1996 Jan; 21(1): 29～35
4[4]Kapur S, Zipursky R, Remington G, et al. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997 Nov;154(11): 1525～1529
5[5]William M, Glazer MD. Dose loxapine have "Atypical" properties?clinical evidence. J C lin Psychiatry. 1999 ;60 (supple 10): 42～46
6[6]Peter F, Buckley, MD. The role of typical and atypical antipsychotics medication in the management of agitation and aggression. J Clin Psychiatry. 1999 ;60(supple 10): 52～60
7[7]Meltzer HY, Jayathilake K. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard - dose loxapine? J Clin Psychiatry. 1999; 60 Suppl 10: 47～51
8[9]Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999; 60 Suppl 10: 20～30
